Dermal Abyss is a project between the Massachusetts Institute of Technology (MIT) and Harvard Medical School. They have developed the biosensing tattoo ink with four biosensors which can change the color in response to the changing blood sugar (glucose), pH and sodium levels in men or women. The biosensing tattoo inks can replace the traditional tattoo inks. They can monitor the random medical condition of the patients.
The Dermal Abyss (D-abyss) tattoo inks can read the concentration of sodium, pH and glucose levels in the interstitial fluid of the skin. They are providing an option to monitor health complications such as an electrolyte imbalance, alkalosis, acidosis, diabetes and hypertension. The Dermal Abyss (or d-abyss) (biosensors, biosensitive inks) are less invasive.
The ink color (of the d-abyss tattoo) can change with respect to the change in the parameters in the interstitial fluid. The color of the ink turns into "brown" color from "blue" color as the blood sugar levels increases. The ink of the pH biosensor tattoo can change from "purple" color to "pink" color.
The biosensing tattoo inks are very useful to insulin-dependent patients of diabetes as they need to check the blood sugar levels with a finger prick testing device (an invasive procedure) between four and ten times daily.
The leader of the project was Katia Canepa Vega, MIT's Media Lab. The researchers have done the preliminary evaluation. Now, the biosensitive tattoo inks are in the testing process.
A study shows a higher risk of heart failure in male patients in early-stage prostate cancer who underwent androgen deprivation therapy (ADT). The researchers followed 7,637 men between 1998 and 2008, who are diagnosed with localized prostate cancer (cancer is contained within the prostate gland).
A 12-year follow-up study has found that 30 percent of the participants underwent androgen deprivation therapy (also known as androgen suppression therapy).
The study also found that 81 percent of the enhanced risk of heart failure among prostate cancer patients without cardiovascular diseases (CVD) at the start of the study and underwent androgen deprivation therapy.
Among men with cardiovascular disease (CVD) at the start of the study, the study shows a 44 percent of the enhanced risk of arrhythmia (abnormal and irregular heart rate) and three times enhanced risk of conduction disorder of the heart (electrical impulses of the heart).
The study results accounted for risk factors such as tobacco use, body mass index (BMI), prostate-specific antigen levels, hypertension or high blood pressure levels (BP), high blood sugar (glucose) levels (type 2 diabetes) and cardiovascular diseases (CVD).
The researchers say that the patients of localized prostate cancer should consider the effects of the androgen deprivation therapy (ADT) and they should discuss with their doctor. Patients should take steps to modify their lifestyle to reduce the risk and symptoms associated with cardiovascular diseases (CVD) if the person is undergoing androgen deprivation therapy (ADT).
The following table shows the survival rate with localized or regional prostate cancer without any treatment.
The lead author of the study was Reina Haque, Ph.D., MPH, research scientist II, Department of Research & Evaluation, Kaiser Permanente Southern California. The study was published on August 24, 2017, in the British Journal of Cancer. Title of the article was "Cardiovascular disease risk and androgen deprivation therapy in patients with localized prostate cancer: a prospective cohort study."
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.